Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-Interferon: An observational study

Journal of NeuroVirology

Volumn 4, Issue 3, 1998, Pages 324-332

  Huang, S S ^a   Skolasky, R L ^a   Dal Pan, G J ^a   Royal III, W ^a   McArthur, J C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha interferon; HIV; Magnetic resonance imaging; PML

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON;

AMNESIA; APHASIA; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; DISEASE COURSE; DYSARTHRIA; DYSPHAGIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MENTAL HEALTH; MOTOR COORDINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; RETROSPECTIVE STUDY; SURVIVAL; SYMPTOM;

EID: 0031839156     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.3109/13550289809114533     Document Type: Article

References (34)

1. Albrecht H, Hoffman C, Degen O, et al (1997), Highly active antiretroviral (HAART) significantly improved the prognosis of patients (pts) with HIV-associated progressive multifocal leukoencephalopathy (abstract). 37th ICCAC San Francisco, 1997.
2. Berger JR, Concha M (1995). Progressive multifocal leukoencephalopathy: the evolution of a disease once considered rare. J Neurovirol 1: 5-18.
3. Berger JR, Kaszovitz B, Post JD, Dickinson G (1987). Progressive multifocal leukoencephalopathy associated with Human Immunodeficiency Virus Infection. Ann Intern Med 107: 78-87.
4. Berger JR, Levy RM (1997). AIDS and the nervous system. Philadelphia: Lippencott-Raven.
5. Berger JR, Mucke L (1988). Prolonged survival and partial recovery in AIDS-associated Progressive Multifocal Leukoencephalopathy. Neurology 38: 1060-1065.
6. Berger JR, Pall L, McArthur JC, Colin H, Cimoch P, Evans B, et al (1992). A pilot study of recombinant alpha 2A interferon in the treatment of AIDS-related progressive multifocal leukoencephalopathy (abstract). Neurology 42(Suppl 3): 257.
7. Britton CB (1992). Progressive multifocal leukoencephalopathy: Disease progression, stabilization. and response to intrathecal ara-C in 26 patients (abstract). VIII International Conference on AIDS/HI STD World Congress. Amsterdam, the Netherlands July 19-24.
8. Brooks BR, Walker DL (1984). Progressive multifocal leukoencephalopathy. Neurol Clin 2: 229-313.
9. Colosimo C, Legon P, Martelli M, Tumminelli F, Mandelli F (1992). Alpha-interferon therapy in a case of probable Progressive Multifocal Leukoencephalopathy. Acta Neurologica Belgica 92(1): 24-29.
10. Counihan TJ, Venna N, Craven D, Savin TD (1996). Alpha interferon in AIDS-related progressive multifocal leukoencephalopathy. Neuro AIDS 1: 79.
11. Dianzani F, Antonelli G, Amicucci P, Cefano A, Pintus C (1989). Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients. J Interferon Res 9(Suppl 1): S33-S36.
12. Elliot BC, Aromin I, Flanigan TP, Mileno M (1996). Leukoencephalopathv with combined antiretroviral therapy (abstract). Internatinal Conf AIDS 11(2): 222.
13. Gall SA (1995). Human papillomavirus infection and therapy with interferon. Am J of Obs and Gyn 172(4 pt 2): 1354-1359.
14. Gillespie SM, Chang Y, Lemp G, Arthur R, Buchbinder S, Steimle A, et al (1991). Progressive multifocal leukoencephalopathy in persons infected with Human Immunodefiency Virus, San Francisco, 1981-1989. Ann of Neurol 30(4): 597-604.
15. Glesby MJ, Hoover DR (1996). Survivor Treatment Selection Bias in Observational Studies: Examples from the AIDS Literature. Ann Intern Med 124: 999-1005.
16. Gutterman JU (1994). Cytokine therapeutics: lessons from interferon alpha. Proc Nat Acad Sci 91(4): 1198-1205.
17. Hall C, Timpone J, Dafni I, Antonijevic Z, et al (1997). ARA-C treatment of PML in AIDS patients (abstract). 4th International Conference on Retroviruses and Opportunistic Infections. Washington DC, USA 1997.
18. Henry K, Worley J, Sullivan C et al (1997). Documented improvement in late stage manifestations of AIDS after starting ritonavir in combination with two reverse transcriptase inhibitors (abstract). Opportun Infect Jan 22-26: 130.
19. Houff SA, Major EO, Katz D, Kufta C, Sever J, Pittaluga S, Roberts J, Bitt J, Saini N, Lux W (1988). Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 318: 301-305.
20. Kurschel E, Metz-Kurschel U, Niederle N, Aulbert E (1991). Investigations on the subclinical and clinical nephrotoxicity of Interferon alpha-2B in patients with myeloproliferative syndromes. Renal Failure 13(2-3): 87-93.
21. Lane HC, Davey B, Kovacs JA, Feinberg J, Metcalf JA, Herpin B, et al (1990). Interferon-alpha in patients with asymptomatic Human Immunodeficiency Virus (HIV) infection. Ann Intern Med 112: 805-811.
22. Major EO, Amemiya K, Tornatore CS, Houff SA, Berger JR (1992). Pathogenesis and Molecular Biology of Progressive Multifocal Leukoencephalopathy, the JC Virus-Induced Demyelinating Disease of the Human Brain. Clin Microbio Rev 1: 49-73.
23. Major EO, Ault GS (1995). Progressive multifocal leukoencephalopathy: clinical and laboratory observations on a viral induced demyelinating disease in the immunodencient patient. Current Opinion in Neurology 8: 184-190.
24. Portegies P, Algra PR, Hollak CEM, Prins JM, Reiss P, Valk J, et al (1991). Response to cytarabine in Progressive Multifocal Leukoencephalopathy in AIDS. Lancet 337: 680-681.
25. Radwanski E, Perentesis G, Jocobs S, Oden E, Affrime M, Symchowicz S, et al (1987). Pharmacokinetics of interferon alpha-2b in healthy volunteers. J Clin Pharmacol 27: 432-435.
26. Ronnblom LE, Alm GV, Oberg KE (1991). Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 115(3): 178-183.
27. Shah K, Nathanson N (1976). Human exposure to SV40: Review and comment. Am J Epidem 103(1): 1-12.
28. Smith RA, Norris F, Palmer D, et al (1985). Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration. Clin Pharmacol Ther 37: 85-88.
29. Spiegel RJ, Jacobs SL, Treuhaft MW (1989). Antiinterferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective. J Interferon Res 9(Suppl 1): S17-S24.
30. Steiger MJ, Tarnesby G, Gabe S, McLaughlin J, Schapire AH (1993). Successful outcome of Progressive Multifocal Leukoencephalopathy with cytarabine and interferon. Ann Neurol 33(4): 407-411.
31. Trapp BD, Small JA, Pulley BA, Khoury G, Scangos GA (1988). Dysmyelination in transgenic mice containing JC virus early region. Ann Neurol 23: 38-48.
32. Vial R, Descotes J (1994). Clinical toxicity of the interferons. Drug Saf 10(2): 115-150.
33. Walker DL, Padgett BL (1993). The epidemiology of human polyomaviruses. In: Polyomaviruses and Human Neurological Diseases. New York: Alan R. Liss, Inc., pp 99-106.
34. ZuRhein G, Chou SM (1965). Particles resembling papovaviruses in human cerebral demyelinating disease. Science 148: 1477-1479.